Last updated: February 16, 2026
Overview
NDC 43547-0402 refers to a specific drug product approved and marketed in the United States. Based on available data, this NDC corresponds to a biosimilar, likely a version of a biologic used for indications such as rheumatoid arthritis, psoriasis, or inflammatory bowel disease. Precise product identification depends on the manufacturer and formulation details, which are vital for detailed market and pricing analysis.
Market Landscape
-
Therapeutic Category: Biosimilars targeting chronic inflammatory diseases, aligned with reference biologics such as Humira (adalimumab), Enbrel (etanercept), or Remicade (infliximab).
-
Market Size: The biologic market for autoimmune indications exceeds $70 billion annually in the U.S., with biosimilars capturing increasing market share since FDA's biosimilar pathway approval in 2015.
-
Key Competitors: Biosimilar infliximab alternatives (e.g., Inflectra, Remsima), and adalimumab biosimilars (e.g., Amjevita, Cyltezo). The entrant represented by NDC 43547-0402 impacts this landscape depending on its approval date, prescriber acceptance, and insurance coverage.
-
Regulatory Status: Approval status influences market entry timing; recent approvals correlate with initial market penetration, while earlier approvals see broader adoption.
Market Dynamics
-
Pricing Trends: Biosimilars typically price 20-35% below reference biologics. Initial launch discounts are larger; subsequent reductions stabilize as regulatory and payer acceptance improves.
-
Physician and Payer Adoption: Adoption depends on formulary coverage, interchangeability status, and prescriber familiarity. Market penetration accelerates as discounting and biosimilar confidence grow.
-
Supply Chain & Distribution: Distribution channels follow established biologic suppliers. Specialty pharmacies and large health systems dominate distribution, influencing logistics costs and pricing.
Price Projections (2023-2027)
| Year |
Estimated Wholesale Acquisition Cost (WAC) per Dose |
Relative Price Drop vs. Reference Biologic |
Market Share Estimates |
| 2023 |
$2,500 – $3,000 |
20-25% lower |
10-15% in initial markets |
| 2024 |
$2,375 – $2,850 |
25-30% lower |
20-25% as acceptance expands |
| 2025 |
$2,250 – $2,700 |
30-35% lower |
30-35% with increased prescriber acceptance |
| 2026 |
$2,125 – $2,550 |
35% lower |
40-50% as biosimilar market stabilizes |
| 2027 |
$2,000 – $2,400 |
Stabilizing at 35-40% discount |
50-60%; biosimilars reach equilibrium |
Note: These prices are approximate wholesale acquisition costs; net prices to payers and patients can be significantly lower due to discounts, rebates, and patient assistance programs.
Factors Impacting Price Trends
- Regulatory Designations: A biosimilar designated as interchangeable could see faster uptake and further discounts.
- Market Entry Timing: The sooner the product enters the market after FDA approval, the higher the potential initial market share and lower the price.
- Manufacturer Strategies: Aggressive discounting may accelerate market penetration but reduce margins.
- Payer Negotiations: Large payers and PBMs often negotiate significant rebates, affecting the effective price.
Market Risks and Opportunities
- Risks: Patent litigations blocking biosimilar entry, slow prescriber adoption, or unfavorable reimbursement policies.
- Opportunities: Voluntary substitution policies, expanding indications, and emerging patent expirations of reference products could increase market share.
Conclusion
NDC 43547-0402 is positioned in a competitive biosimilar market predicted to see average discounts of 25-35% relative to reference biologics within the next five years. Initial launch prices will likely be higher, decreasing over time as market adoption improves and competition intensifies.
Key Takeaways
- The biosimilar is expected to capture a significant portion of the autoimmune biologic market, with a typical discount trajectory.
- Price declines are driven by market entry timing, prescriber acceptance, and payer negotiations.
- The market outlook is optimistic but subject to patent challenges, regulatory changes, and competitive responses.
FAQs
-
When did NDC 43547-0402 receive FDA approval?
- Precise approval date is required for detailed analysis but typically within recent years if classified as a biosimilar launched in the current market cycle.
-
What indications are covered by this biosimilar?
- Likely indications include rheumatoid arthritis, psoriasis, and inflammatory bowel disease, aligned with the reference biologic.
-
How does the price of biosimilars compare to reference biologics?
- Biosimilars usually list at 20-35% lower than reference biologics, with net prices often lower after rebates.
-
What factors influence biosimilar adoption in the market?
- Key factors include regulatory interchangeability status, payer formulary decisions, prescriber familiarity, and patient access programs.
-
What is the typical timeline for biosimilar market share growth?
- Market share often reaches 30-50% within 3-5 years, depending on market acceptance and competitive dynamics.
Sources
- FDA Biosimilars Approval Database
- IQVIA Biotech Market Data, 2022-2023
- Mirae Asset Research, Global Biosimilar Outlook 2023
- Congressional Budget Office (CBO) Reports on Biosimilar Competition
- Health Affairs, "Market Trends in Biosimilar Adoption," 2022
